In their study, they included all the controlled and non-controlled, randomized and non-randomized trials using bone marrow or GM-CSF mobilized peripheral blood cells, and they concluded that autologous bone marrow therapy is a feasible, relatively safe and potentially effective therapeutic strategy for PAD patients. The gene discussed is CSF2; the disease is peripheral arterial disease.